机译:铬母细胞瘤患者样品中κAb,MyCN mycn和Alk配体碱碱(AlK配体碱碱碱的分析,具有染色体臂2p重排
Department of Laboratory MedicineInstitute of Biomedicine Sahlgrenska Academy University of;
Department of Laboratory MedicineInstitute of Biomedicine Sahlgrenska Academy University of;
Department of Laboratory MedicineInstitute of Biomedicine Sahlgrenska Academy University of;
Department of Medical Biochemistry and Cell BiologyInstitute of Biomedicine Sahlgrenska Academy;
Bioinformatics Core FacilitySahlgrenska Academy University of GothenburgGothenburg Sweden;
Childhood Cancer Research Unit Department of Women's and Children's HealthKarolinska;
Department of Medical Biochemistry and Cell BiologyInstitute of Biomedicine Sahlgrenska Academy;
Department of Medical Biochemistry and Cell BiologyInstitute of Biomedicine Sahlgrenska Academy;
Childhood Cancer Research Unit Department of Women's and Children's HealthKarolinska;
Department of Laboratory MedicineInstitute of Biomedicine Sahlgrenska Academy University of;
Department of Medical Biochemistry and Cell BiologyInstitute of Biomedicine Sahlgrenska Academy;
ALK; ALKAL2; Augmentor; FAM150; MYCN; neuroblastoma;
机译:铬母细胞瘤患者样品中κAb,MyCN mycn和Alk配体碱碱(AlK配体碱碱碱的分析,具有染色体臂2p重排
机译:对神经母细胞瘤的荟萃分析揭示了用MYCN扩增的偏斜ALK突变谱
机译:第二代ALK抑制剂alectinib有效地诱导人神经母细胞瘤细胞中的凋亡,抑制TH-Mycn转基因神经母细胞瘤小鼠模型中的肿瘤生长
机译:受体酪氨酸激酶ALK的配体的发现和表征:AUG-alpha,AUG-beta和肝素。
机译:alk配体alkal2强调了Mycn驱动的神经母细胞瘤的缺失
机译:没有新的内含子19保持alk转录物(Alk-I19)和MyCN扩增与神经母细胞瘤患者的优异临床结果相关联